UNSPSC 51313701: Quinotolast

This classification denotes a histamine-1 receptor antagonist with the molecular formula C17H12N6O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SUC3551A8U, chemically known as 4h-quinolizine-3-carboxamide, 4-oxo-1-phenoxy-n-1h-tetrazol-5-yl but generally known as quinotolast, which bears US NIH Compound Identifier 65871. European Medicines Agency schedules Quinotolast in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10220MIG.

UNSPSC 51313701 Quinotolast is a Commodity code whose recent state and local activity reflects procurement of pharmaceutical products and drug-management systems rather than the specific active ingredient its name denotes. State and local health agencies, counties, and multistate cooperative purchasing organizations are soliciting under this code to source naloxone and drug deactivation systems, generic pharmaceuticals, and over-the-counter products through competitive bidding and cooperative purchasing vehicles. Issuing bodies include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances administering joint procurement on behalf of member jurisdictions across multiple states. The work spans one-time or annual supply purchases of finished pharmaceutical products, with quarterly or regular delivery schedules to specified distribution points, alongside longer-term framework contracts that establish pricing and product availability for ongoing member-agency purchases.

Recent activity concentrates in Florida and Texas, with multistate cooperative purchasing extending activity to participating jurisdictions including Oregon and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through July 26, 2026, with quarterly deliveries and vendor responsibility for shipping costs. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, with response due April 3, 2026. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson), with proposals due March 26, 2026 and contract effectiveness July 1, 2026. The MMCAP procurement requires NDC compliance, cGMP certification, DSCSA compliance, and $2 million to $5 million in insurance coverage, with performance penalties of $200 to $1,500 per violation.